Delfi Diagnostics is a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection.
Delfi's mission is to develop an innovative blood test for detection of cancer when it is most curable.
Delfi Diagnostics was founded in 2019 by Victor Velculescu. The company is headquartered in Baltimore, Maryland.
Delfi's technology leverages advances in machine learning and recent discoveries in the genome-wide fragmentation profiles of cell free DNA to create a novel approach to detecting evidence of a tumor from a blood sample, while also pinpointing the tumor's location in the body.
Delfi is applying this platform technology to develop a range of products designed to detect specific cancers, such as lung cancer, in at-risk individuals and to identify any of multiple cancers in any individual.
Delfi's technology, first described in Nature in 20191, demonstrated sensitivity from 57% to more than 99% among seven cancer types at 98% specificity in a study of more than 400 individuals.
Delfi is backed by OrbiMed, Menlo Ventures, Samsara Biocapital, Illumina Ventures, Foresite Capital, Northpond Ventures, AV8 Ventures, Windham Venture Partners and others. The company raised $100M in Series A round on Jan 12, 2021. This brings Delfi's total funding to $105.5M to date.